Clinical Trial Search

Phase 3 N=1,046 Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy

Rheumatoid Arthritis

Primary: Short-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to…

Bristol-Myers Squibb Results Jun 2011 10.9% serious AE View details

Phase 3 N=1,643 Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers

Meningococcal Meningitis · Measles · Mumps

Primary: Measles, Mumps, Rubella, and Varicella (MMRV) Antibody Values in Participants Who Received MMRV Vaccine (Groups 2 and 4 Only) — 98; 98; 95; 95 Percentage of Participants

Sanofi Pasteur, a Sanofi Company Results Jun 2011 4.1% serious AE View details

Phase 3 N=1,118 A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers

Meningococcal Meningitis · Measles · Mumps

Primary: Percentage of Participants With Antibody Titers ≥ 8 After Visit 2 Menactra® Vaccination as Measured by Serum Bactericidal Assay Using Human Complement (SBA-HC) — 96; 93…

Sanofi Pasteur, a Sanofi Company Results Jun 2011 3.8% serious AE View details

Phase 3 N=444 Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2

Neoplasms, Breast

Primary: Overall Survival (OS) at 53 Months — 27.8; 20.5 months — p=0.0062

Novartis Pharmaceuticals Results Jun 2011 17.6% serious AE View details

Phase 3 N=938 Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)

Pneumococcal Infections

Primary: Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC Relative to 23vPS (Vax 1 / Year 0) — 81; 55; 55; 49 geometric mean titer

Wyeth is now a wholly owned subsidiary of Pfizer Results May 2011 3.3% serious AE View details

Phase 3 N=166 Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

Cryopyrin-Associated Periodic Syndromes · Familial Cold Autoinflammatory Syndrome · Muckle Wells Syndrome

Primary: The Number of Participants With Adverse Events (AEs), Death, Serious Adverse Events (SAEs), Discontinuation of Study Drug Due to an AE, Infections and Infestations and…

Novartis Results May 2011 10.8% serious AE View details

Phase 3 N=1,065 Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.

Bone Loss · Breast Cancer

Primary: Percentage Change in Bone Mineral Density (BMD) of the Lumbar Spine (L2-L4) at 12 Months of Therapy. — 2.208; -3.617 Percentage change in BMD

Novartis Pharmaceuticals Results May 2011 24.3% serious AE View details

Phase 3 N=501 Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo For Treatment Of Post-Surgical Pain From Hysterectomy

Pain, Postoperative

Primary: Worst Pain Using the Modified Brief Pain Inventory - Short Form (m-BPI-sf) — 7.1; 7.2; 7.4 Units on a scale — p=0.1378

Pfizer's Upjohn has merged with Mylan to form… Results May 2011 7.1% serious AE View details

Phase 3 N=514 Olanzapine Treatment of Patients With Bipolar I Disorder

Depression, Bipolar

Primary: Change From Baseline to Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score (Acute Phase) — 29.36; 28.69; -14.26; -11.71 units on a scale — p=0.018

Eli Lilly and Company Results May 2011 3.0% serious AE View details

Phase 3 N=327 Long-Term Study of Gabapentin Enacarbil (GEn, XP13512) vs. Placebo in Patients With Restless Legs Syndrome.

Restless Legs Syndrome

Primary: Percentage of Participants Who Experienced a Relapse During the Double-Blind Treatment Period — 22.7; 9.4 percentage of participants — p=0.0158

XenoPort, Inc. Results May 2011 1.2% serious AE View details

Phase 3 N=257 Efficacy and Safety of Valsartan and Amlodipine (± HCTZ) in Adults With Moderate, Inadequately Controlled Hypertension

Hypertension

Primary: Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Core Phase of the Study — -9.13 mmHg

Novartis Results May 2011 0.2% serious AE View details

Phase 3 N=2,719 Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults

Influenza

Primary: Immunogenicity Results After Each Vaccination by Vaccine Group, in Participants 18 to 64 Years of Age — 129; 126; 135; 134 Participants

Novartis Results May 2011 5.7% serious AE View details

Phase 3 N=654 Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 Months

Influenza

Primary: Antibody Responses After the First and Second Vaccinations — 19; 9; 15; 19 Percentages of Subjects

Novartis Vaccines Results May 2011 3.4% serious AE View details

Phase 3 N=859 Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

Primary: Change From Baseline in the Alzheimer's Disease Assessment Scale - Japan Cognitive Subscale (ADAS-J Cog) — 24.8; 25.2; 25.0; 26.1 units on a scale

Novartis Pharmaceuticals Results May 2011 8.5% serious AE View details

Phase 3 N=103 Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease

Crohn's Disease

Primary: Occurrence of at Least One Treatment-emergent Adverse Event During This Study (Maximum 122 Weeks) — 12; 15; 32; 30 subjects

UCB Pharma Results May 2011 14.6% serious AE View details